Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. (Q54372714)
Jump to navigation
Jump to search
scientific article published on 16 May 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. |
scientific article published on 16 May 2011 |
Statements
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. (English)
Hermann Einsele
Patrick A Baeuerle
Max S Topp
Peter Kufer
Nicola Gökbuget
Mariele Goebeler
Matthias Klinger
Svenja Neumann
Heinz-A Horst
Thorsten Raff
Andreas Viardot
Mathias Schmid
Matthias Stelljes
Markus Schaich
Evelyn Degenhard
Rudolf Köhne-Volland
Monika Brüggemann
Heike Pfeifer
Dirk Nagorsen
Margit Schmidt
Ralf Lutterbuese
Carsten Reinhardt
Michael Kneba
Gert Riethmüller
Dieter Hoelzer
Gerhard Zugmaier
Ralf C Bargou
16 May 2011
29
18
2493-2498